Overcoming the innate immune response to small interfering RNA.
about
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeuticsActivation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoterPseudovirions as vehicles for the delivery of siRNAsiRNA Delivery from an Injectable Scaffold for Wound TherapyTechnologies for controlled, local delivery of siRNAProgress toward in vivo use of siRNAs-IICytokines as biomarkers of nanoparticle immunotoxicityRescue of non-human primates from advanced Sudan ebolavirus infection with lipid encapsulated siRNAMicroRNAs Used in Combination with Anti-Cancer Treatments Can Enhance Therapy EfficacySilencing disease genes in the laboratory and the clinicA simple Bayesian estimate of direct RNAi gene regulation events from differential gene expression profiles.Mechanistically probing lipid-siRNA nanoparticle-associated toxicities identifies Jak inhibitors effective in mitigating multifaceted toxic responses.siRNA silencing of keratinocyte-specific GFP expression in a transgenic mouse skin model.Sequence determinants of innate immune activation by short interfering RNAs.Sequence-non-specific effects of RNA interference triggers and microRNA regulators.Minimal-length short hairpin RNAs: the relationship of structure and RNAi activityEffects of chemical modification on the potency, serum stability, and immunostimulatory properties of short shRNAs.Minimal-length Synthetic shRNAs Formulated with Lipid Nanoparticles are Potent Inhibitors of Hepatitis C Virus IRES-linked Gene Expression in MicePreclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing.Oligonucleotide-based strategies to combat polyglutamine diseases.Clinical status of duplex RNADegradable lipid nanoparticles with predictable in vivo siRNA delivery activity.Synergistic effects between analogs of DNA and RNA improve the potency of siRNA-mediated gene silencingEffect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters.Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.RNAi-based therapeutics-current status, challenges and prospectsInnovative strategy for microRNA delivery in human mesenchymal stem cells via magnetic nanoparticles.Deficiency in either 4E-BP1 or 4E-BP2 augments innate antiviral immune responsesClaudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis.Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivoBase modification strategies to modulate immune stimulation by an siRNA.AAV-mediated in vivo knockdown of luciferase using combinatorial RNAi and U1i.siRNA for Influenza Therapy.In vivo sustained release of siRNA from solid lipid nanoparticles.Atelocollagen-mediated systemic delivery prevents immunostimulatory adverse effects of siRNA in mammals.Buffering capacity and size of siRNA polyplexes influence cytokine levels.Lack of correlation between predicted and actual off-target effects of short-interfering RNAs targeting the human papillomavirus type 16 E7 oncogene.Liposome delivery of microRNA-145 to mesenchymal stem cells leads to immunological off-target effects mediated by RIG-I.Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice.Gene therapy progress and prospects: synthetic polymer-based systems.
P2860
Q24616751-E12691EC-002A-45F0-B831-D946EAD1E212Q24624648-41A9759D-8CDF-4CD4-A4D7-7C9588BBE000Q24634231-532F121C-A729-4106-8041-491AAF95523EQ27026234-6D3A7978-9B1B-426A-9C73-0AFC5CFD3DDFQ28087657-C0828894-5382-4AE2-AA08-767CDB5FC426Q28255877-6139D3E0-F29D-4C3D-BE14-6F3C629A2A72Q28383550-708F9777-1BEC-4067-99F5-6BFB39FE9CD5Q28396399-DDA95F42-C2EE-4D2E-85C1-C54EA8587911Q28829013-6A5E564E-230D-4B5F-9938-870CD4FFDA02Q29039090-095D23CB-5C9F-4481-82FC-1A2CA288A933Q31012608-EE9E1C58-57BE-4EC8-AFB8-57DD4329FED7Q33393397-4312E979-52D7-4C88-A87E-8E8C4ECAC324Q33454280-905953DD-8856-4238-9212-0083C8840271Q33486742-55718B18-05C0-4635-8D7A-E62C49C48B1EQ33566425-7E2981EC-4049-46D7-9C7F-297EA845A6B1Q33572896-766DEEF7-CDC0-424D-B247-132CED7B3DA3Q33572902-D553527C-B2A2-42B3-BE1C-C447E825D1A8Q33637385-DDFECDFD-0028-4541-A4BA-D6A7C0FC1C97Q33752590-59224B67-8A13-4B44-8312-BCC43EFB90A3Q33791247-A4C4A3FF-123E-498B-A18A-7C8BB461BEB3Q33869361-3858F7A8-C3AD-4ECB-81C2-A10CA4575A85Q33954008-8379FB41-F762-4225-B929-026751D90467Q34020246-98E45481-06F9-47C8-A06E-4B1614C054DCQ34080079-574471F0-E019-4C08-BCBE-36799704FBD9Q34622662-F45D5522-45CE-42DA-BF7E-64C398A091B2Q34659612-A99368A0-24D6-4546-81BF-2FEA4E278E73Q34736652-F57DCCDF-F228-4B7E-8D04-B9FC82AE1B69Q34756913-9F771C74-FDBB-4226-B2FF-1136CC7C8EE0Q34942127-6BA4C015-B3D0-4DEE-8650-05E1E1BB7EA8Q34946937-021F1295-C790-4412-BA1D-100DDC600018Q35112225-4C8664D2-D5B7-4D21-A39C-DD9B8C8064DBQ35204876-70F74756-3F12-46F7-B044-EF2BCA5C20B3Q35261103-B1B1FF99-A12D-4440-86CE-F77E923BB906Q35635763-40E16649-E42E-45B7-9A6E-C20A51E61FEFQ35750040-DBDA7E42-B6F7-4A54-90C2-23D360BFE22FQ36460487-3A9D2034-4797-42FD-9736-83E7B0C464D9Q36594145-4DB4C439-B4E3-420C-A4C3-58763B6A271EQ36915116-82EC3FB6-80B9-4796-9E06-BD33B4E2C3B0Q37111373-F5D0700E-27A1-4104-A852-87D78A9FC5D7Q37182756-07C49617-CBEE-4363-AC4E-BCD9AAC66EF8
P2860
Overcoming the innate immune response to small interfering RNA.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Overcoming the innate immune response to small interfering RNA.
@en
Overcoming the innate immune response to small interfering RNA.
@nl
type
label
Overcoming the innate immune response to small interfering RNA.
@en
Overcoming the innate immune response to small interfering RNA.
@nl
prefLabel
Overcoming the innate immune response to small interfering RNA.
@en
Overcoming the innate immune response to small interfering RNA.
@nl
P356
P1433
P1476
Overcoming the innate immune response to small interfering RNA.
@en
P2093
Adam Judge
Ian MacLachlan
P304
P356
10.1089/HUM.2007.179
P577
2008-02-01T00:00:00Z